Targeting IL-34 in chronic inflammation

Drug Discovery Today

Volumn 19, Issue 8, 2014, Pages 1212-1216

  Masteller, Emma L ^a   Wong, Brian R ^a  

^a FIVE PRIME THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 820; ARRY 382; BLOCKING ANTIBODY; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; CYTOKINE; FPA 008; IMCCS 4; INTERLEUKIN 34; JNJ 40346527; MCS 110; NEUTRALIZING ANTIBODY; PD 0360324; PHOSPHOTRANSFERASE INHIBITOR; PLX 3397; PLX 5622; PROTEIN TYROSINE KINASE; RG 7155; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN DERIVATIVE;

CELL VIABILITY; CHRONIC INFLAMMATION; DRUG TARGETING; HUMAN; INFLAMMATORY DISEASE; LANGERHANS CELL; MACROPHAGE ACTIVATION; MICROGLIA; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; DRUG EFFECTS; INFLAMMATION; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; INTERLEUKINS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION;

EID: 84906326798     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.05.016     Document Type: Review

References (40)

1. H. Lin et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome Science 320 2008 807 811
2. X.M. Dai et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects Blood 99 2002 111 120
3. M. Baud'huin et al. Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis J. Pathol. 221 2010 77 86
4. Z. Chen et al. The critical role of IL-34 in osteoclastogenesis PLoS One 6 2011 e18689
5. S. Wei et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells J. Leukoc. Biol. 88 2010 495 505
6. T. Chihara et al. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation Cell Death Differ. 17 2010 1917 1927
7. R.A. Barve et al. Transcriptional profiling and pathway analysis of CSF-1 and IL-34 effects on human monocyte differentiation Cytokine 63 2013 10 17
8. S. Nandi et al. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation Dev. Biol. 367 2012 100 113
9. M. Greter et al. Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia Immunity 37 2012 1050 1060
10. Y. Wang et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia Nat. Immunol. 13 2012 753 760
11. Y. Nakamichi et al. Spleen serves as a reservoir of osteoclast precursors through vitamin D-induced IL-34 expression in osteopetrotic op/op mice Proc. Natl. Acad. Sci. U. S. A. 109 2012 10006 10011
12. D. Malhotra et al. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks Nat. Immunol. 13 2012 499 510
13. F. Yamane et al. CSF-1 receptor-mediated differentiation of a new type of monocytic cell with B cell-stimulating activity: its selective dependence on IL-34 J. Leukoc. Biol. 95 2014 19 31
14. S. Nandi et al. Receptor-type protein-tyrosine phosphatase zeta is a functional receptor for interleukin-34 J. Biol. Chem. 288 2013 21972 21986
15. K.A. Sauter et al. Pleiotropic effects of extended blockade of CSF1R signaling in adult mice J. Leukoc. Biol. 2014 Epub ahead of print
16. V. Garceau et al. Pivotal advance: avian colony-stimulating factor 1 (CSF-1), interleukin-34 (IL-34), and CSF-1 receptor genes and gene products J. Leukoc. Biol. 87 2010 753 764
17. H. Liu et al. The mechanism of shared but distinct CSF-1R signaling by the non-homologous cytokines IL-34 and CSF-1 Biochim. Biophys. Acta 1824 2012 938 945
18. X. Ma et al. Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R Structure 20 2012 676 687
19. J. Felix et al. Human IL-34 and CSF-1 establish structurally similar extracellular assemblies with their common hematopoietic receptor Structure 21 2013 528 539
20. J.A. Hamilton, and A. Achuthan Colony stimulating factors and myeloid cell biology in health and disease Trends Immunol. 34 2013 81 89
21. D.A. Hume, and K.P. MacDonald Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling Blood 119 2012 1810 1820
22. L. Fend et al. Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts PLoS One 8 2013 e73310
23. S.M. Pyonteck et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression Nat. Med. 19 2013 1264 1272
24. J.A. Hamilton, and P.P. Tak The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases Arthritis Rheum. 60 2009 1210 1221
25. R.T. Paniagua et al. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis Arthritis Res. Ther. 12 2010 R32
26. M. Chemel et al. Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients Ann. Rheum. Dis. 71 2012 150 154
27. S.J. Hwang et al. Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis Arthritis Res. Ther. 14 2012 R14
28. S.J. Moon et al. Increased levels of interleukin 34 in serum and synovial fluid are associated with rheumatoid factor and anticyclic citrullinated peptide antibody titers in patients with rheumatoid arthritis J. Rheumatol. 40 2013 1842 1849
29. Y. Tian et al. Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: possible association with disease progression via interleukin-17 production J. Interferon Cytokine Res. 33 2013 398 401
30. H. Eda et al. Proinflammatory cytokines, IL-1beta and TNF-alpha, induce expression of interleukin-34 mRNA via JNK- and p44/42 MAPK-NF-kappaB pathway but not p38 pathway in osteoblasts Rheumatol. Int. 31 2011 1525 1530
31. H. Eda et al. Macrophage-colony stimulating factor and interleukin-34 induce chemokines in human whole blood Cytokine 52 2010 215 220
32. S. Garcia et al. Colony-stimulating factor (CSF) receptor 1 blockade overcomes overlapping effects of M-CSF and interleukin-34 on myeloid differentiation and gene expression to reduce inflammation in human and murine models of rheumatoid arthritis. Arthritis Rheum. 64 Suppl. 10 2012
33. F. Ciccia et al. IL-34 is overexpressed in the inflamed salivary glands of patients with Sjogren's syndrome and is associated with the local expansion of pro-inflammatory CD14(bright)CD16+ monocytes Rheumatology 52 2013 1009 1017
34. C.P. Mavragani, and H.M. Moutsopoulos Sjogren's syndrome Annu. Rev. Pathol. 9 2014 273 285
35. R. Bethunaickan et al. Comparative transcriptional profiling of 3 murine models of SLE nephritis reveals both unique and shared regulatory networks PLoS One 8 2013 e77489
36. J. Menke et al. Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis J. Am. Soc. Nephrol. 20 2009 2581 2592
37. C. Zhang et al. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor Proc. Natl. Acad. Sci. U. S. A. 110 2013 5689 5694
38. Z.A. Radi et al. Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury Am. J. Pathol. 179 2011 240 247
39. M. Korkosz et al. Monoclonal antibodies against macrophage colony-stimulating factor diminish the number of circulating intermediate and nonclassical (CD14(++)CD16(+)/CD14(+)CD16(++)) monocytes in rheumatoid arthritis patient Blood 119 2012 5329 5330
40. K.L. Wong et al. The three human monocyte subsets: implications for health and disease Immunol. Res. 53 2012 41 57